3rd Oct 2023 18:19
GSK PLC - London-based pharmaceutical company - On Monday, announces that the UK Medicines & Health Products Regulatory Agency has authorised a new indication for Jemperli, also known as dostarlimab. The drug is used as a treatment for some types of endometrial cancer and an be used to treat patients that have a tumour abnormality called mismatch repair deficient/microsatellite instability-high when the cancer is at an advanced stage when first diagnosed or has returned after previous treatment. It is now authorised to be used together with chemotherapy to slow the progression of these cancers. GSK says it is the first medicine licensed as first line treatment for primary advanced or recurrent endometrial cancer.
Current stock price: 1,485.00 pence
12-month change: up 12%
By Heather Rydings, Alliance News senior economics reporter
Comments and questions to [email protected]
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Related Shares:
Glaxosmithkline